Evidence map›Paper›PMID 25485185›Full record

ArticleDrug delivery and translational research2012

Multilayer thin film coatings capable of extended programmable drug release: application to human mesenchymal stem cell differentiation.

Jinkee Hong, Luis M Alvarez, Nisarg J Shah, Linda G Griffith, Byeong-Su Kim, Kookheon Char, Paula T Hammond

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery and translational research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jinkee HongDepartment of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue Cambridge, Massachusetts 02139, USA ; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue Cambridge, Massachusetts 02139, USA ; School of Chemical and Biological Engineering, Intelligent Hybrids Research Center, Seoul National University, Seoul 151-744, Republic of Korea.
Luis M AlvarezDepartment of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue Cambridge, Massachusetts 02139, USA ; Joint Program Executive Office for Chemical and Biological Defense, Ft Detrick, MD 21702, USA.
Nisarg J ShahDepartment of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue Cambridge, Massachusetts 02139, USA ; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue Cambridge, Massachusetts 02139, USA.
Linda G GriffithDepartment of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue Cambridge, Massachusetts 02139, USA ; Department of Mechanical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue Cambridge, Massachusetts 02139, USA.
Byeong-Su KimDepartment of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue Cambridge, Massachusetts 02139, USA.
Kookheon CharSchool of Chemical and Biological Engineering, Intelligent Hybrids Research Center, Seoul National University, Seoul 151-744, Republic of Korea.
Paula T HammondDepartment of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue Cambridge, Massachusetts 02139, USA ; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 77 Massachusetts Avenue Cambridge, Massachusetts 02139, USA.

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9M
Nanoscale Electrostatic Assemblies for Multi-Agent Drug Delivery fromR01AG029601 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HAMMOND, PAULA T · 2007 to 2011
$1.9M
NCI NIH HHS P30 CA014051NIA NIH HHS R01 AG029601
6 · The paper itself

Abstract

The promise of cellular therapy lies in healing damaged tissues and organs in vivo as well as generating tissue constructs in vitro for subsequent transplantation. Adult stem cells are ideally suited for cellular therapies due to their pulripotency and the ease with which they can be cultured on novel functionalized substrates. Creating environments to control and successively driving their differentiation toward a lineage of choice is one of the most important challenges of current cell-based engineering strategies. In recent years, a variety of biomedical platforms have been prepared for stem cell cultures, primarily to provide efficient delivery of growth or survival factors to cells and a conducive microenvironment for their growth. Here, we demonstrate that repeating tetralayer structures composed of biocompatible poly(methacrylic acid) (PMAA)/poly(acryl amide) (PAAm)/poly(methacrylic acid) (PMAA)/poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) micelles arrayed in layer-by-layer (LbL) films can serve as a payload region for dexamethasone (dex) delivery to human mesenchymal stem cells (MSCs). This architecture can induce MSC differentiation into osteoblasts in a dose-dependent manner. The amount of dex loaded in the films is controlled by varying the deposition conditions and the film thickness. Furthermore, release of dex is also controlled by changing the amount of covalent crosslinking of multilayers via thermal treatments. The multilayer architecture including payload and cell-adhesion region introduced here are well suited for extended cell culture thus affording the important and protective effect of both dex release and immobilization. These films may find applications in the local delivery of immobilized therapeutics for biomedical applications, as they can be deposited on a wide range of substrates with different shapes, sizes, and composition.

Indexed as

controlled releasedexamethasonedifferentiationHuman mesenchymal stem cellsLayer-by-layermultilayer

Identifiers

PMID25485185
PMCPMC4255723

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.